科濟藥業-B(02171.HK):益傑一致行動集團已購買合共190.35萬股
格隆匯6月27日丨科濟藥業-B(02171.HK)發佈公吿,董事會獲公司主要股東益傑生物技術控股有限公司(“益傑生物”)吿知,益傑生物及其一致行動人士(統稱“益傑一致行動集團”)擬於公吿日期起計約十二個月內,在公開市場收購公司股份。董事會於近日獲益傑生物吿知,益傑一致行動集團已於本年度內直至2024年6月25日(收市後)購買合共190.35萬股股份,佔已發行股份總數約0.33%。
增持股份後,益傑一致行動集團持有約2.17億股股份,佔已發行股份總數約37.78%。董事會認為,增持股份彰顯主要股東對公司的前景及增長潛力充滿信心以及對公司長期投資價值的認可。
此外,截至2024年6月25日收市後,公司已購回合共398.55萬股股份,佔已發行股份總數約0.69%。購回股份所用資金來自非IPO募集資金,其中包括業務發展收入、利息收入及其他補貼。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.